Search Results

November 2021 Addex's strategic partner The Janssen Pharmaceutical Companies of Johnson & Johnson, Inc allosteric modulation-based drug discovery and development, today announced that Janssen Pharmaceuticals, Inc The successful completion of this Phase 1 safety program will enable centers in Japan to be included

and Changes Name from ShouTi "San Francisco and Shanghai – August 1, 2022 – Structure Therapeutics Inc (Structure Therapeutics), formerly known as ShouTi Inc., today announced it closed an oversubscribed

May 2022 "MONTREAL (CANADA) – May 17, 2022 – Inversago Pharma Inc. Vraniak served as the Chief Financial Officer of electroCore, Inc. and was a key member of the management Vraniak served as an executive in various innovative healthcare and technology companies including GE

Kenakin joined Glaxo Inc in RTP where he remained for 25 years through iterations of Glaxo Inc, GlaxoWellcome

path from academic neuroendocrinology to introducing molecular biology and molecular pharmacology into Glaxo Foord is a physiologist and pharmacologist who spent more than two decades at Glaxo, Glaxo Wellcome, contributed to the identification of RAMPs in the CGRP receptor system, deorphanization of several GPCRs including and practical considerations in choosing receptor-rich tissues. 05:00 — Transition from academia to Glaxo

Crinetics, he was senior director and head of endocrinology and metabolism at Neurocrine Biosciences, Inc he initiated and led the effort to discover and develop orally active, nonpeptide GnRH antagonists, including Prior to Neurocrine, from 1995 to 1998, he co-founded ScienceMedia Inc. to develop eLearning solutions